ClinicalTrials.gg
CompletedNCT01103323Updated Jun 24, 2015Results posted

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Metastatic Colorectal Cancer, sponsored by Bayer. Completed at 171 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-24.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
Largest of 58
760 · median 55
Started
2010
the only one that year
Phase 3
7 of 59
1 open now
Registered
2nd of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one has the largest enrollment of the 58 interventional ones that give a count, is the only one that started in 2010, is one of 7 in phase 3, and was the 2nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC

Read the detailed description

All participants received Best Supportive Care. Acronyms used in Adverse events section: Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Common Terminology Criteria for Adverse Events (CTCAE), International Normalized Ratio (INR), Central nervous system (CNS), Acute respiratory distress syndrome (ARDS), Cranial nerves (CN), Disseminated Intravascular Coagulation (DIC), Cardiac troponin T (cTnT).

Abbreviation used in Results section: Data Monitoring Committee (DMC). Adverse event collection will be covered in Adverse events section.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological documentation of adenocarcinoma of the colon or rectum
  • Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an setting should have progressed during or within 6 months of completion of adjuvant therapy
  • Patients with measurable or non
  • (ECOG) Performance Status of \</= 1
  • of at least 3 months
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Unstable/uncontrolled cardiac disease
  • History of arterial or venous thrombotic or embolic events
  • Symptomatic brain or meningeal tumors
  • Patients with evidence or history of bleeding diathesis
  • Interstitial lung disease - Persistent proteinuria >/= grade 3
  • Unresolved toxicity > grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity \</= Grade 2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
760 participants (actual)

Study arms

  • Experimental
    Regorafenib (Stivarga, BAY73-4506)+BSC

    Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).

    Drug: Regorafenib (Stivarga, BAY73-4506) · Other: Best Supportive Care (BSC)

  • Placebo comparator
    Placebo+BSC

    Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).

    Drug: Placebo · Other: Best Supportive Care (BSC)

Interventions

  • 160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

  • DrugPlacebo

    matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

  • OtherBest Supportive Care (BSC)

    BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.

    Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).

Secondary outcomes

  1. Progression-free Survival (Based on Investigator's Assessment)

    Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.

    Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.

  2. Objective Tumor Response

    The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.

    Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.

  3. Disease Control

    Disease control was defined as the percentage of patients whose best response was not PD \[sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\] (ie, CR \[tumor disappears\], PR \[sum of lesion sizes decreased at least 30% from baseline\] or SD (stable disease)). SD included if at least 6 weeks after randomization.

    Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.

  4. Tumor Response

    A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.

    Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.

07

Results

Posted Nov 19, 2012
Limitations and caveats
At 2nd IA, pre-specified O'Brien-Fleming-type efficacy boundary was crossed. DMC concluded OS result positive and after positive risk benefit assessment, recommended unblinding of study. OS from 2nd IA are the final formal and definitive results.

Participant flow

Without/Before Drug Switch
Participant flow — Without/Before Drug Switch
MilestoneRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Started505255
Participants received treatment500253
Completed429237
Not completed7618
Withdrew: Adverse event507
Withdrew: Withdrawal by subject175
Withdrew: Protocol violation20
Withdrew: Physician decision20
Withdrew: Did not receive study treatment52
Withdrew: Switch to regorafenib04
Switched From Placebo to Regorafenib
Participant flow — Switched From Placebo to Regorafenib
MilestoneRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Started04
Completed03
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryOverall Survival

Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.

Time frame:
From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).
Reported as:
Median · Days
Overall Survival
DaysRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Overall Survival196 (178 to 222)151 (134 to 177)
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506)+BSC vs Placebo+BSC · Log Rank · p = 0.005178 (According to protocol specified O'Brien-Fleming type alpha spending function and 432 death events at 2nd IA, the pre-specified alpha (false positive rate) for this analysis was 0.009279 (1-sided).) · Hazard ratio (hr): 0.774 · 95% CI 0.636 to 0.942Two treatment groups compared using a stratified log-rank test, stratified by same stratification factors as randomization. Hazard ratio (Regorafenib / Placebo) and its 95% confidence interval calculated using Cox model, stratified by same factors.
SecondaryProgression-free Survival (Based on Investigator's Assessment)

Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.

Time frame:
From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Reported as:
Median · Days
Progression-free Survival (Based on Investigator's Assessment)
DaysRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Progression-free Survival (Based on Investigator's Assessment)59 (57 to 65)52 (51 to 53)
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506)+BSC vs Placebo+BSC · Log Rank · p = <0.000001 (Comparison based on pre-specified alpha level of 0.025 (1-sided).) · Hazard ratio (hr): 0.494 · 95% CI 0.419 to 0.582Hazard ratio (Regorafenib / Placebo)
SecondaryObjective Tumor Response

The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.

Time frame:
From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Reported as:
Number · Percentage of participants
Objective Tumor Response
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Objective Tumor Response1.00.4
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506)+BSC vs Placebo+BSC · Cochran-Mantel-Haenszel · p = 0.188432 (Comparison based on pre-specified alpha level of 0.025 (1-sided).) · Difference: -0.60 · 95% CI -1.74 to 0.53Difference = Placebo - Regorafenib 160 mg
SecondaryDisease Control

Disease control was defined as the percentage of patients whose best response was not PD \[sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\] (ie, CR \[tumor disappears\], PR \[sum of lesion sizes decreased at least 30% from baseline\] or SD (stable disease)). SD included if at least 6 weeks after randomization.

Time frame:
From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Reported as:
Number · Percentage of participants
Disease Control
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Disease Control41.014.9
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506)+BSC vs Placebo+BSC · Cochran-Mantel-Haenszel · p = <0.000001 (Comparison based on pre-specified alpha level of 0.025 (1-sided).) · Difference: -25.94 · 95% CI -32.06 to -19.82Difference = Placebo - Regorafenib 160 mg
SecondaryTumor Response

A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.

Time frame:
From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Reported as:
Number · Percentage of participants
Tumor Response
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSC
Complete Response (CR)00
Partial Response (PR)1.00.4
Stable Disease (SD)42.814.5
Progressive Disease (PD)49.580.0
Non CR/Non PD0.80.4
Not applicable0.20
Not assessed5.74.7

Adverse events

Collected over AE was collected up to 30 days after end of study treatment (per protocol) over a period of approximately 3.7 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib (BAY73-4506)+BSC—232/500 (46.4%)489/500 (97.8%)
Placebo+BSC—103/253 (40.7%)229/253 (90.5%)
Placebo - Regorafenib After Unblinding—2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventRegorafenib (BAY73-4506)+BSCPlacebo+BSCPlacebo - Regorafenib After Unblinding
AscitesGastrointestinal disorders1/5002/2531/4
VomitingGastrointestinal disorders3/5000/2531/4
Death not associated with CTCAE term, Disease progression NOSGeneral disorders16/5006/2531/4
Constitutional symptoms - OtherGeneral disorders34/50023/2530/4
FeverGeneral disorders17/5002/2530/4
Liver dysfunctionHepatobiliary disorders17/5005/2530/4
Obstruction, GI, Small bowel NOSGastrointestinal disorders4/5007/2530/4
Pain, Abdomen NOSGeneral disorders13/5002/2530/4
Dyspnea (Shortness of breath)Respiratory, thoracic and mediastinal disorders12/5004/2530/4
Obstruction, GI, ColonGastrointestinal disorders9/5006/2530/4
Most frequent other events
Showing 10 of 58
Most frequent other events
EventRegorafenib (BAY73-4506)+BSCPlacebo+BSCPlacebo - Regorafenib After Unblinding
FatigueGeneral disorders318/500115/2530/4
DiarrheaGastrointestinal disorders218/50044/2532/4
FeverGeneral disorders136/50040/2532/4
Weight lossGeneral disorders167/50030/2532/4
AnorexiaGastrointestinal disorders239/50073/2530/4
Hand-foot skin reactionSkin and subcutaneous tissue disorders235/50019/2531/4
Voice changesRespiratory, thoracic and mediastinal disorders160/50016/2531/4
HypertensionCardiac disorders155/50021/2531/4
Mucositis (functional/symptomatic), Oral cavityGastrointestinal disorders145/50012/2530/4
Rash/DesquamationSkin and subcutaneous tissue disorders145/50013/2531/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Regorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSCTotal
Mean60.7 (22 to 82)60.1 (25 to 85)60.5 (22 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSCTotal
Female194102296
Male311153464
Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment
Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment(Participants)Regorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSCTotal
0265146411
1240109349
KRAS mutation
KRAS mutation(Participants)Regorafenib (Stivarga, BAY73-4506)+BSCPlacebo+BSCTotal
No20594299
Yes273157430
Unknown27431
08

Study locations

171 sites
  • Beverly Hills, California 90211, United States
  • Los Angeles, California 90033, United States
  • Los Angeles, California 90036, United States
  • Mission Hills, California 91345, United States
  • Orange, California 92868, United States
  • Redlands, California 92374, United States
  • Santa Maria, California 93454, United States
  • Aventura, Florida 33180, United States
  • Jacksonville, Florida 32224, United States
  • Peoria, Illinois 61615-7828, United States
  • Cedar Rapids, Iowa 52403, United States
  • New Orleans, Louisiana 70121, United States
  • Ann Arbor, Michigan 48106, United States
  • Rochester, Minnesota 55905, United States
  • St. Cloud, Minnesota 56303, United States
  • Jefferson City, Missouri 65109, United States
  • Neptune, New Jersey 07754, United States
  • New York, New York 10011, United States
  • Fargo, North Dakota 58122, United States
  • Toledo, Ohio 43623, United States
  • Scranton, Pennsylvania 18510, United States
  • Charleston, South Carolina 29414, United States
  • Sumter, South Carolina 29150, United States
  • Dallas, Texas 75390-9110, United States
  • Salt Lake City, Utah 84106, United States
  • Green Bay, Wisconsin 54303, United States
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1122AAL, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1264AAA, Argentina
  • Rosario, Santa Fe S2000PBJ, Argentina
  • San Miguel de Tucumán, Tucuman T4000GTB, Argentina
  • Capital Federal-Buenos Aires, C1426ANZ, Argentina
  • Concord, New South Wales 2139, Australia
  • St Leonards, New South Wales 2065, Australia
  • Woolloogabba, Queensland 4102, Australia
  • Woodville South, South Australia 5011, Australia
  • Footscray, Victoria 3011, Australia
  • Parkville, Victoria 3050, Australia
  • Bruxelles - Brussel, 1000, Belgium
  • Bruxelles - Brussel, 1070, Belgium
  • Bruxelles - Brussel, 1200, Belgium
  • Edegem, 2650, Belgium
  • Leuven, 3000, Belgium
  • Roeselare, 8800, Belgium
  • Salvador, Bahia 41830-492, Brazil
  • Fortaleza, Ceará 60160-230, Brazil
  • Belo Horizonte, Minas Gerais 30110-090, Brazil
  • Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Vancouver, British Columbia V5Z 4E6, Canada
  • Winnipeg, Manitoba R2H 2A6, Canada
  • Moncton, New Brunswick E1C 6Z8, Canada
  • London, Ontario N6A 4L6, Canada
  • Mississauga, Ontario L5M 2N1, Canada
  • Oshawa, Ontario L1G 2B9, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Montreal, Quebec H3T 1E2, Canada
  • Quebec, G1R 2J6, Canada
  • Guangzhou, Guangdong 510060, China
  • Guangzhou, Guangdong 510515, China
  • Nanjing, Jiangsu 210003, China
  • Nanjing, Jiangsu 210009, China
  • Qingdao, Shandong 266100, China
  • Beijing, 100021, China
  • Beijing, 100071, China
  • Changchun, 130021, China
  • Chongqing, 400038, China
  • Chongqing, 400042, China
  • Fuzhou, 350014, China
  • Fuzhou, 350025, China
  • Ha'erbin, 150040, China
  • Hanghzou, 310009, China
  • Shanghai, 200001, China
  • Shanghai, 200030, China
  • Tianjin, 300060, China
  • Brno, 65 653, Czech Republic
  • Hradec Kralove, 500 05, Czech Republic
  • Olomouc, 775 20, Czech Republic
  • Praha, 18081, Czech Republic
  • Avignon, 84000, France
  • Le Mans Cedex 2, 72015, France
  • Lille Cedex, 59020, France
  • Lille Cedex, 59037, France
  • Marseille, 13005, France
  • Montpellier, 34298, France
  • Paris, 75651, France
  • Reims, 51092, France
  • Rennes, 35042, France
  • Strasbourg Cedex, 67085, France
  • Freiburg, Baden-Württemberg 79106, Germany
  • Karlsruhe, Baden-Württemberg 76137, Germany
  • Mannheim, Baden-Württemberg 68167, Germany
  • Stuttgart, Baden-Württemberg 70199, Germany
  • München, Bayern 81377, Germany
  • München, Bayern 81737, Germany
  • München, Bayern 81925, Germany
  • Hannover, Niedersachsen 30625, Germany
  • Oldenburg, Niedersachsen 26133, Germany
  • Essen, Nordrhein-Westfalen 45122, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Leverkusen, Nordrhein-Westfalen 51375, Germany
  • Porta Westfalica, Nordrhein-Westfalen 32457, Germany

Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. PubMed 23177514 ↗
  • Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, Unger C, Kratzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15. PubMed 22421192 ↗
  • Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13. PubMed 26184520 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jul 2011 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 14, 2010
Start
Apr 2010
Primary completionActual
Jul 2011
CompletionActual
Jan 2014
Results first posted
Nov 19, 2012
Last update
Jun 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01103323
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 14, 2010
Start date
Apr 2010
Primary completion
Jul 2011
Completion
Jan 2014
Results posted
Nov 19, 2012
Last update
Jun 24, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion